diabetic kidney disease
Conditions
Interventions
treatment group:Bushen Xiaoyu Xiezhuofang granules, 2 times a day, 2 bags each time, taken with boiling water
control group:Bushen Xiaoyu Xiezhuo granules mimics, 2 times a day, 2 bags each time, taken with boiling water
Sponsors
The First Affiliated Hospital of Zhejiang Chinese Medicine University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Consistent with the diagnosis of diabetic nephropathy (DKD); (2) The 24-hour urine protein was quantified at 0.5~3.5g; (3) CKD stage 2-3 (eGFR 30-89ml/min, estimated by CKD-EPI formula); (4) With hypertension (blood pressure can be controlled = 130-140/80-90mmHg with medication) or without hypertension; ?HbA1c<8.0% ; (6) TCM syndrome differentiation is kidney deficiency and stasis syndrome; (7) Have taken ACE inhibitors/ARB drugs for 2 weeks or more, and have taken irbesartan tablets for 2 weeks or more after the introduction period, with a daily dosage of 150-300mg; (8) Age 18~70 years old, gender is not limited; (9) Those who voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Blood pressure > 180/90mmHg or 5.5mmol/L or <3.5mmol/L after clinical treatment; (3) Patients whose serum creatinine has doubled in the past six months (4) History of unilateral or bilateral renal artery stenosis; (5) Other serious diabetic complications and serious macrovascular events in the past six months, such as cerebral hemorrhage, large-scale cerebral infarction, and acute myocardial infarction; (6) Patients with various infectious diseases in the past 4 weeks; (7) Combined with primary and other secondary kidney diseases; (8) Combined with other serious diseases, such as hematologic diseases, malignant tumors, etc.; (9) Serious psychological or psychiatric abnormalities; (10) Pregnant or lactating women; (11) Patients with a history of allergy to the components in this study drug; (12) Subjects who are participating in clinical trials of other drugs. Note: If any of the above conditions are met, this study is excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24-hour urine protein quantification;Urine albumin-creatinine ratio;serum creatinine;blood urea nitrogen;blood uric acid; | — |
Secondary
| Measure | Time frame |
|---|---|
| TCM Syndrome Points;serum albumin;total triglycerides;total cholesterol;Low-density lipoprotein;High-density lipoprotein;high-sensitivity C-reactive protein;tumor necrosis factor alpha;Monocyte Chemoattractant Protein-1;interleukin 6;Transforming growth factor beta;Connective tissue growth factor;Platelet-derived growth factor; | — |
Countries
China
Contacts
Public ContactChen Hongbo
The First Affiliated Hospital of Zhejiang Chinese Medicine University
Outcome results
None listed